Trial
NCT06411639
Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Sjogren Disease
Intervention
ianalumab
Why stopped
Strategic decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-01-27